MedTrace Logo

Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents

NCT00837837 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-10-23

No results posted yet for this study

Summary

The purpose of this study is to examine the pharmacokinetic parameters of chlorpheniramine in children and adolescents.

Conditions

Interventions

DRUG

Chlorpheniramine

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-21
Primary Completion
2009-02-02
Completion
2009-02-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00837837 on ClinicalTrials.gov